A study of AB-PA01 for the treatment of pseudomonas aeruginosa infections in patients with cystic fibrosis.
Phase of Trial: Phase I
Latest Information Update: 05 Oct 2016
At a glance
- Drugs AB PA01 (Primary)
- Indications Pseudomonal infections
- Focus Adverse reactions
- 05 Oct 2016 New trial record
- 09 Aug 2016 According to a AmpliPhi Biosciences media release, the company expects to initiate this study in 2017.